MC2 Therapeutics A/S Sustainability Profile
MC2 Therapeutics A/S, headquartered in Denmark, is a pioneering biopharmaceutical company focused on developing innovative therapies for dermatological conditions. Founded in 2015, the company has rapidly established itself in the industry, particularly in the field of topical treatments that leverage its proprietary drug delivery technology. With a commitment to enhancing patient outcomes, MC2 Therapeutics offers unique products designed to improve the efficacy and tolerability of existing therapies. Their flagship offerings include advanced formulations that address unmet medical needs in skin health, setting them apart in a competitive market. Recognised for its scientific excellence, MC2 Therapeutics has achieved significant milestones, including successful clinical trials and partnerships that bolster its position as a leader in dermatology. The company continues to expand its operational reach, aiming to transform the landscape of skin treatment through innovation and patient-centric solutions.
DitchCarbon Score
How does MC2 Therapeutics A/S's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Other Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
MC2 Therapeutics A/S's score of 26 is lower than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
MC2 Therapeutics A/S's reported carbon emissions
MC2 Therapeutics A/S, headquartered in Denmark (DK), currently does not report any carbon emissions data, as indicated by the absence of specific figures. Consequently, there are no recorded emissions across Scope 1, Scope 2, or Scope 3 categories. Additionally, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing carbon emissions at this time. Without emissions data or reduction initiatives, MC2 Therapeutics A/S appears to be in the early stages of addressing climate commitments within the industry context. As the company progresses, it may consider aligning with industry standards and frameworks to enhance its sustainability efforts and transparency regarding carbon emissions.
How Carbon Intensive is MC2 Therapeutics A/S's Industry?
How Carbon Intensive is MC2 Therapeutics A/S's Location?
MC2 Therapeutics A/S's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
MC2 Therapeutics A/S has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.